Head-to-head evidence
BCD-264 vs CID-103
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
BCD-264
Marketed by Biocad
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
CID-103
Developed by CASI Pharmaceuticals, Inc.
NCT04758767 · Phase 1 · completed
All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-264's landscape · CID-103's landscape